All posts

CGY stock keeps “Outperform” rating at RBC

Following the company’s fourth quarter results, RBC analyst Maxim Matushansky has retained his “Outperform” rating on Calian Group (Calian Group Stock Quote, Chart, News, Analysts, Financials TSX:CGY), though he has lowered his expectation slightly.

On November 27, CGY reported its Q4, 2023 results. The company posted Adjusted EBITDA of $20-million on revenue of $176-million, a topline that was up ten per cent over the same period a year prior.

“We finished the year with a record quarter as revenues, gross margin and adjusted EBITDA reached new historical highs,” CEO Kevin Ford said. “In FY23 we generated double-digit revenue growth with all four segments contributing. Our adjusted EBITDA remained flat. With two recent acquisitions and adjustments in our operating costs, we are poised to see continued increase in our profitability. Given the ongoing robust demand for our products and services, the contribution from recent acquisitions and the benefits from our restructuring plan, we are confident in our ability to post another record year. At the midpoint of our guidance range this translates into revenue and adjusted EBITDA growth of 15 per cent and 32 per cent, respectively, over FY23.”

As reported in the Globe and Mail, Matushansky has lowered his price target on Calian Group from $70.00 to $65.00. The stock closed November 28 at $52.08.

Tagged with: cgy
Staff

Recent Posts

Trulieve Cannabis is a buy, Beacon says

Trulieve Cannabis (Trulieve Cannabis Stock Quote, Chart, News, Analysts, Financials CSE:TRUL) delivered a strong start to fiscal 2025, beating high-end… [Read More]

3 hours ago

Green Thumb Industries should be a core holding for cannabis investors, analyst says

Green Thumb Industries (Green Thumb Industries Stock Quote, Chart, News, Analysts, Financials CSE:GTII) delivered a steady first quarter and remains… [Read More]

3 hours ago

5N Plus just delivered an “exceptional” quarter, this analyst says

5N Plus (5N Plus Stock Quote, Chart, News, Analysts, Financials TSX:VNP) blew past expectations in the first quarter of 2025,… [Read More]

19 hours ago

Kinaxis is still undervalued, ATB Capital says

Kinaxis (Kinaxis Stock Quote, Chart, News, Analysts, Financials TSXV:KXS) delivered first-quarter results that met expectations, with record adjusted EBITDA and… [Read More]

19 hours ago

Spectral Medical is “fundamentally undervalued”, Paradigm says

Paradigm Capital analyst Scott McAuley is maintaining a "Buy" rating and $2.30 target on Spectral Medical (Spectral Medical Stock Quote,… [Read More]

24 hours ago

Is Ballard Power a buy?

Ballard Power’s (Ballard Power Stock Quote, Chart, News, Analysts, Financials NASDAQ:BLDP) disappointing Q1 2025 results prompted Roth Capital Partners analyst… [Read More]

24 hours ago